Daporinad

Drug Profile

Daporinad

Alternative Names: APO866; FK 866; NMPRTs

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator Astellas Pharma GmbH
  • Developer TopoTarget Switzerland
  • Class Acrylamides; Antineoplastics; Piperidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Nicotinamide phosphoribosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Malignant melanoma

Most Recent Events

  • 27 Jul 2015 No recent reports of development identified - Phase-II for Cutaneous T-cell lymphoma in the European Union and Switzerland (IV)
  • 02 Jun 2015 TopoTarget terminates a phase-II trial in Cutaneous T-cell lymphoma in European Union and Switzerland due to lack of efficacy (NCT00431912)
  • 19 Sep 2011 No development reported - Phase-II for Malignant melanoma in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top